CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 112 enrolled
Drug / intervention
JDS-HF3.0dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07408115
NCT07408115N/ACompleted
CompareCT.gov

Effect of the Dietary Supplement Bonafide-HF3.0 on Women Who Experience Vasomotor Symptoms: An Open Label Experience Trial

Bonafide Health·interventional·Posted Feb 12, 2026·Updated Feb 12, 2026

In Brief

A clinical study evaluating JDS-HF3.0 for Hot Flashes and 8 related conditions. Completed, enrolled 112 participants across 1 site.

Detailed Summary

The goal of this study is to evaluate the efficacy of a neurokinin 1,3 antagonist on improving vasomotor symptoms (VMS) and overall menopause symptoms in women between the ages of 40-70. The primary research question is whether taking the study product daily for 4 weeks with an optional 8 week extension, significantly reduces the severity and frequency of menopause-related symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedFeb 12, 2026
Enrollment StartMay 24, 2024
Primary CompletionDec 18, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5 months ago

Interventions

JDS-HF3.0dietary

Active Supplement JDS-HF3.0